Becton Dickinson to Pay $175 Million for Misleading Investors on Alaris Infusion Pump
Becton, Dickinson and Company (BD), a New Jersey-based medical device manufacturer, has agreed to pay a $175 million civil penalty to the Securities and Exchange Commission (SEC). The settlement resolves allegations that BD misled investors about significant risks associated with its Alaris infusion pump, a product that once contributed about 10% of the company’s profits.